Prime Medicine, Inc Common Stock

Yahoo Finance • 4 days ago

Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day

MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has secured exclusive licenses from Prime Capital Investments Inc. for the rights to certain Beach... Full story

Yahoo Finance • 4 days ago

Groupe Prime Drink obtient des licences exclusives pour Beach Day Every Day en Amérique du Nord

MONTRÉAL, 06 févr. 2026 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE: PRME) (« Prime » ou la « Société ») est heureuse d'annoncer qu'elle a obtenu des licences exclusives de Prime Capital Investments Inc. pour les droits de certaine... Full story

Yahoo Finance • last month

LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases

Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating and $6 price target. The firm highlighte... Full story

Yahoo Finance • 2 months ago

Prime Drink Group Announces Private Placement

MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- PrimeDrink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minim... Full story

Yahoo Finance • 2 months ago

Groupe Prime Drink annonce un placement privé

MONTRÉAL, 17 déc. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce qu’elle procédera à un placement privé d'unités de la Société (les « unités ») sans l'entremise d'un courtier, afin de... Full story

Yahoo Finance • 2 months ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication o... Full story

Yahoo Finance • 3 months ago

Prime Medicine GAAP EPS of -$0.32 misses by $0.06, revenue of $1.2M misses by $1.6M

* Prime Medicine press release [https://seekingalpha.com/pr/20298659-prime-medicine-reports-third-quarter-2025-financial-results-and-provides-business-updates] (PRME [https://seekingalpha.com/symbol/PRME]): Q3 GAAP EPS of -$0.32 misses b... Full story

Yahoo Finance • 3 months ago

CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitryp... Full story

Yahoo Finance • 3 months ago

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitryp... Full story

Yahoo Finance • 3 months ago

Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment o... Full story

Yahoo Finance • 3 months ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host... Full story

Yahoo Finance • 5 months ago

Prime Drink Group Provides Bi-Weekly MCTO Status Report

MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 15, and August 29, 2025, the Company voluntarily applied for an... Full story

Yahoo Finance • 5 months ago

Groupe Prime Drink fournit un rapport bihebdomadaire sur le statut du MCTO

MONTRÉAL, 12 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce que, conformément à ses communiqués du 30 juillet, du 15 août et du 29 août 2025, la Société a volontairement déposé... Full story

Yahoo Finance • 5 months ago

Prime Drink Group Terminates Rights Offering and Announces Private Placement

MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has terminated its previously disclosed rights offering and that it is proceeding with a non-brokered private p... Full story

Yahoo Finance • 5 months ago

Groupe Prime Drink met fin au placement de droits et annonce un placement privé

MONTRÉAL, 04 sept. 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce qu’elle a mis fin à son placement de droits précédemment divulgué et qu’elle procédera à un placement privé d'unités... Full story

Yahoo Finance • 6 months ago

Prime Drink Group receives extension for annual financial filings

MONTREAL - Prime Drink Group Corp. (CSE:PRME), a beverage company with a market capitalization of $477.21 million, has received an extension to file its annual financial statements for the period ended March 31, 2025, the company announced... Full story

Yahoo Finance • 6 months ago

Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company at the forefront of gene editing technology, focusing on developing treatments for serious genetic diseases. With a market capitalization of $499.5 million and a beta of 2.41, t... Full story

Yahoo Finance • 6 months ago

Guggenheim cuts Prime Medicine stock price target to $5 from $18

Investing.com - Guggenheim lowered its price target on Prime Medicine (NASDAQ:PRME) to $5.00 from $18.00 on Wednesday, while maintaining a Buy rating on the gene editing company’s stock. Currently trading at $3.46, the stock sits below Inv... Full story

Yahoo Finance • 6 months ago

Prime Medicine stock price target lowered to $10 at Chardan on cash update

Investing.com - Chardan Capital Markets lowered its price target on Prime Medicine (NASDAQ:PRME) to $10.00 from $12.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter results. According to InvestingPro... Full story

Yahoo Finance • 6 months ago

Arch venture fund XII buys Prime Medicine shares worth $9.99m

Arch Venture Fund XII, L.P. purchased 3,030,300 shares of Prime Medicine , Inc. (NASDAQ:PRME) on August 1, 2025, at a price of $3.30 per share, in a transaction totaling $9,999,990. The stock currently trades at $4.04, representing a 22%... Full story